VistaGen Therapeutics (VTGN)
NASDAQ:VTGN
Want to see VTGN full AI Analyst Report?
Total Valuation
VistaGen Therapeutics has a market cap or net worth of $27.50M. The enterprise value is -$7.13M.
Market Cap$27.50M
Enterprise Value-$7.13M
Share Statistics
VistaGen Therapeutics has 41,032,450 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding41,032,450
Owned by Insiders0.36%
Owned by Institutions21.48%
Financial Efficiency
VistaGen Therapeutics’s return on equity (ROE) is -1.96 and return on invested capital (ROIC) is -197.26%.
Return on Equity (ROE)-1.96
Return on Assets (ROA)-1.43
Return on Invested Capital (ROIC)-197.26%
Return on Capital Employed (ROCE)-2.02
Revenue Per Employee26.44K
Profits Per Employee-1.45M
Employee Count48
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of VistaGen Therapeutics is ―. VistaGen Therapeutics’s PEG ratio is -0.03.
PE Ratio―
PS Ratio17.15
PB Ratio0.61
Price to Fair Value0.61
Price to FCF-0.33
Price to Operating Cash Flow-0.38
PEG Ratio-0.03
Income Statement
In the last 12 months, VistaGen Therapeutics had revenue of 1.27M and earned -69.69M in profits. Earnings per share was -1.83.
Revenue1.27M
Gross Profit1.27M
Operating Income-72.13M
Pretax Income-69.68M
Net Income-69.69M
EBITDA-71.39M
Earnings Per Share (EPS)-1.83
Cash Flow
In the last 12 months, operating cash flow was -66.44M and capital expenditures -190.00K, giving a free cash flow of -66.63M billion.
Operating Cash Flow-66.44M
Free Cash Flow-66.63M
Free Cash Flow per Share-1.62
Dividends & Yields
VistaGen Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.81
52-Week Price Change-65.82%
50-Day Moving Average0.61
200-Day Moving Average1.85
Relative Strength Index (RSI)60.27
Average Volume (3m)1.23M
Important Dates
VistaGen Therapeutics upcoming earnings date is Aug 6, 2026, TBA (Confirmed).
Last Earnings DateJun 15, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
VistaGen Therapeutics as a current ratio of 3.67, with Debt / Equity ratio of 2.94%
Current Ratio3.67
Quick Ratio3.67
Debt to Market Cap<0.01
Net Debt to EBITDA0.42
Interest Coverage Ratio0.00
Taxes
In the past 12 months, VistaGen Therapeutics has paid 7.00K in taxes.
Income Tax7.00K
Effective Tax Rate>-0.01
Enterprise Valuation
VistaGen Therapeutics EV to EBITDA ratio is 0.11, with an EV/FCF ratio of 0.12.
EV to Sales-6.29
EV to EBITDA0.11
EV to Free Cash Flow0.12
EV to Operating Cash Flow0.12
Balance Sheet
VistaGen Therapeutics has $45.40M in cash and marketable securities with $1.04M in debt, giving a net cash position of $44.36M billion.
Cash & Marketable Securities$45.40M
Total Debt$1.04M
Net Cash$44.36M
Net Cash Per Share$1.08
Tangible Book Value Per Share$0.93
Margins
Gross margin is 41.13%, with operating margin of -5683.69%, and net profit margin of -5491.33%.
Gross Margin41.13%
Operating Margin-5683.69%
Pretax Margin-5490.78%
Net Profit Margin-5491.33%
EBITDA Margin-5625.93%
EBIT Margin-5683.69%
Analyst Forecast
The average price target for VistaGen Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―